Manganese and Movement Disorders: A Review

다국어 초록 (Multilingual Abstract)

Scientific and technological advances achieved with industrial expansion have led to an ever-increasing demand for heavy metals.
This demand has, in turn, led to increased contamination of soil, water and air with these metals. Chronic exposure to metals may be detrimental not only to occupational workers but also to the nonoccupational population exposed to these metals.
Manganese (Mn), a commonly used heavy metal, is an essential cofactor for many enzymatic processes that drive biological functions.
However, it is also a potential source of neurotoxicity, particularly in the field of movement disorders. The typical manifestation of Mn overexposure is parkinsonism, which may be difficult to differentiate from the more common idiopathic Parkinson’s disease. In addition to environmental exposure to Mn, other potential etiologies causing hypermanganesemia include systemic health conditions, total parenteral nutrition and genetic mutations causing Mn dyshomeostasis. In this review, we critically analyze Mn and discuss its sources of exposure, pathophysiology and clinical manifestations. We have highlighted the global public health impact of Mn and emphasize that movement disorder specialists should record a detailed social and occupational history to ensure that a toxic etiology is not misdiagnosed as a neurodegenerative disease. In the absence of a definite therapeutic option, early diagnosis and timely institution of preventive measures are the keys to managing its toxic effects.

참고문헌 (Reference)

• 1 Criswell SR, "[18F]FDOPA positron emission tomography in manganese-exposed workers" 64 : 43-49, 2018
• 2 Lee EY, "Welding-related brain and functional changes in welders with chronic and low-level exposure" 64 : 50-59, 2018
• 3 Canadian Centre for Occupational Health and Safety (CCOHS), "Welding-fumes and gases" Canadian Centre for Occupational Health and Safety
• 4 Zayed J, "Use of MMT in Canadian gasoline : health and environment issues" 39 : 426-433, 2001
• 5 Hosokawa S, "Trace elements and complications in patients undergoing chronic hemodialysis" 55 : 375-379, 1990
• 6 Williams M, "Toxicological Profile for Manganese"
• 7 Jaishankar M, "Toxicity, mechanism and health effects of some heavy metals" 7 : 60-72, 2014
• 8 Ibrahim N, "The sensitivity and specificity of F-DOPA PET in a movement disorder clinic" 6 : 102-109, 2016
• 9 Mezzaroba L, "The role of zinc, copper, manganese and iron in neurodegenerative diseases" 74 : 230-241, 2019
• 10 Myers JE, "The nervous system effects of occupational exposure on workers in a South African manganese smelter" 24 : 885-894, 2003
• 11 Mertz W, "The essential trace elements" 213 : 1332-1338, 1981
• 12 Mehrifar Y, "The effects of occupational exposure to manganese fume on neurobehavioral and neurocognitive functions : an analytical cross-sectional study among welders" 19 : 372-386, 2020
• 13 Blanc PD, "The early history of manganese and the recognition of its neurotoxicity, 1837-1936" 64 : 5-11, 2018
• 14 Rocha E, "Teaching neuroimages : spinocerebellar ataxia type 3 presenting with a cock-walk gait phenotype" 89 : e192-, 2017
• 15 Bowman AB, "Role of manganese in neurodegenerative diseases" 25 : 191-203, 2011
• 16 Kok B, "Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy" 58 : 1516-1517, 2013
• 17 Shulman LM, "Reversal of parkinsonism following liver transplantation" 60 : 519-, 2003
• 18 Qavi AH, "Reversal of acquired hepatocerebral degeneration with living donor liver transplantation" 22 : 125-129, 2016
• 19 Long LL, "Relationship between changes in brain MRI and(1)H-MRS, severity of chronic liver damage, and recovery after liver transplantation" 234 : 1075-1085, 2009
• 20 Criswell SR, "Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels" 69 : 394-397, 2012
• 21 Shin HW, "Recent updates on acquired hepatocerebral degeneration" 7 : 463-, 2017
• 22 Gonzalez-Cuyar LF, "Quantitative neuropathology associated with chronic manganese exposure in South African mine workers" 45 : 260-266, 2014
• 23 Iregren A, "Psychological test performance in foundry workers exposed to low levels of manganese" 12 : 673-675, 1990
• 24 Yoon H, "Protective effects of sodium para-amino salicylate on manganese-induced neuronal death : the involvement of reactive oxygen species" 61 : 1563-1569, 2009
• 25 Andersen O, "Principles and recent developments in chelation treatment of metal intoxication" 99 : 2683-2710, 1999
• 26 Engwa GA, "Poisoning in the modern world: new tricks for an old dog?" IntechOpen 77-99, 2019
• 27 Pouchieu C, "Pesticide use in agriculture and Parkinson’s disease in the AGRICAN cohort study" 47 : 299-310, 2018
• 28 Huang CC, "Parkinsonism induced by chronic manganese intoxication--an experience in Taiwan" 30 : 385-395, 2007
• 29 Andruska KM, "Neuromythology of manganism" 2 : 143-148, 2015
• 30 Josephs KA, "Neurologic manifestations in welders with pallidal MRI T1 hyperintensity" 64 : 2033-2039, 2005
• 31 Chia SE, "Neurobehavioral functions among workers exposed to manganese ore" 19 : 264-270, 1993
• 32 Lucchini R, "Neurobehavioral effects of manganese in workers from a ferroalloy plant after temporary cessation of exposure" 21 : 143-149, 1995
• 33 Ono K, "Myoclonic involuntary movement associated with chronic manganese poisoning" 199 : 93-96, 2002
• 34 Tuschl K, "Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia" 7 : 11601-, 2016
• 35 Chen P, "Metals and Neurodegeneration" 366 : 2016
• 36 Neal AP, "Mechanisms of lead and manganese neurotoxicity" 2 : 99-114, 2013
• 37 Calne DB, "Manganism and idiopathic parkinsonism : similarities and differences" 44 : 1583-1586, 1994
• 38 Kwakye GF, "Manganese-induced parkinsonism and Parkinson’s disease : shared and distinguishable features" 12 : 7519-7540, 2015
• 39 Harischandra DS, "Manganese-induced neurotoxicity: new insights into the triad of protein misfolding, mitochondrial impairment, and neuroinflammation" 13 : 654-, 2019
• 40 Mercadante CJ, "Manganese transporter Slc30a10 controls physiological manganese excretion and toxicity" 129 : 5442-5461, 2019
• 41 Quadri M, "Manganese transport disorder : novel SLC30A10 mutations and early phenotypes" 30 : 996-1001, 2015
• 42 Butterworth RF, "Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy" 10 : 259-267, 1995
• 43 O’Neal SL, "Manganese toxicity upon overexposure : a decade in review" 2 : 315-328, 2015
• 44 Harischandra DS, "Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein" 12 : eaau4543-, 2019
• 45 Mergler D, "Manganese neurotoxicity, a continuum of dysfunction: results from a community based study" 20 : 327-342, 1999
• 46 Bouabid S, "Manganese neurotoxicity : behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission" 136 : 677-691, 2016
• 47 Chen P, "Manganese metabolism in humans" 23 : 1655-1679, 2018
• 48 Winder BS, "Manganese in the air : are children at greater risk than adults" 73 : 156-158, 2010
• 49 Avila DS, "Manganese in health and disease" 13 : 199-227, 2013
• 50 Chen P, "Manganese homeostasis in the nervous system" 134 : 601-610, 2015
• 51 Tuschl K, "Manganese and the brain" 110 : 277-312, 2013
• 52 Aschner M, "Manganese and its role in Parkinson’s disease : from transport to neuropathology" 11 : 252-266, 2009
• 53 Gavin CE, "Manganese and calcium efflux kinetics in brain mitochondria. Relevance to manganese toxicity" 266 : 329-334, 1990
• 54 Guilarte TR, "Manganese and Parkinson’s disease : a critical review and new findings" 118 : 1071-1080, 2010
• 55 Erikson KM, "Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter" 20 : 390-394, 2005
• 56 Barceloux DG, "Manganese" 37 : 293-307, 1999
• 57 Huang CC, "Long-term progression in chronic manganism : ten years of follow-up" 50 : 698-700, 1998
• 58 Anderson JG, "Inhibition of DAT function attenuates manganese accumulation in the globus pallidus" 23 : 179-184, 2007
• 59 Smith EA, "Increased whole blood manganese concentrations observed in children with iron deficiency anaemia" 27 : 65-69, 2013
• 60 Ghosh R, "Hypermanganesemia induced chorea and cognitive decline in a tea seller" 10 : 45-, 2020
• 61 Lucchini RG, "High prevalence of parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries" 50 : 788-800, 2007
• 62 Jan AT, "Heavy metals and human health : mechanistic insight into toxicity and counter defense system of antioxidants" 16 : 29592-29630, 2015
• 63 Health Canada., "Guidelines for Canadian drinking water quality: guideline technical document-manganese" Health Canada
• 64 Anagianni S, "Genetic disorders of manganese metabolism" 19 : 33-, 2019
• 65 Fasano A, "Gait disorders" 19 : 1344-1382, 2013
• 66 Herrero Hernandez E, "Follow-up of patients affected by manganese-induced parkinsonism after treatment with CaNa2EDTA" 27 : 333-339, 2006
• 67 Abdalian R, "Effects of manganese from a commercial multi-trace element supplement in a population sample of Canadian patients on long-term parenteral nutrition" 37 : 538-543, 2013
• 68 Jiang YM, "Effective treatment of manganese-induced occupational parkinsonism with p-aminosalicylic acid : a case of 17-year follow-up study" 48 : 644-649, 2006
• 69 Standridge JS, "Effect of chronic low level manganese exposure on postural balance : a pilot study of residents in Southern Ohio" 50 : 1421-1429, 2008
• 70 Stamelou M, "Dystonia with brain manganese accumulation resulting from SLC30A10mutations : a new treatable disorder" 27 : 1317-1322, 2012
• 71 Racette BA, "Dose-dependent progression of parkinsonism in manganeseexposed welders" 88 : 344-351, 2017
• 72 Ikeda K, "Dopamine transporter imaging in Parkinson disease : progressive changes and therapeutic modification after anti-parkinsonian medications" 58 : 1665-1672, 2019
• 73 Mudgal S, "Development of a risk Assessment for health and environment from the use of metallic additives and a test methodology for that purpose : final report" 2013
• 74 Koksal A, "Chronic manganese toxicity due to substance abuse in Turkish patients" 60 : 224-227, 2012
• 75 Government of Canada, "Canada Occupational Health and Safety Regulations (SOR/86-304)" Department of Justice of Canada
• 76 Kowaltowski AJ, "Ca(2+)-induced mitochondrial membrane permeabilization : role of coenzyme Q redox state" 269 (269): C141-C147, 1995
• 77 Boycott KM, "Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8" 97 : 886-893, 2015
• 78 Dong X, "Atypical neuroimaging findings in patients with acquired hepatocerebral degeneration" 41 : 175-181, 2020
• 79 Sánchez-González C, "Association of plasma manganese levels with chronic renal failure" 31 : 78-84, 2015
• 80 Roels HA, "Assessment of the permissible exposure level to manganese in workers exposed to manganese dioxide dust" 49 : 25-34, 1992
• 81 Fernández-Rodriguez R, "Acquired hepatocerebral degeneration : clinical characteristics and MRI findings" 17 : 1463-1470, 2010
• 82 da Silva CJ, "A preliminary study revealing a new association in patients undergoing maintenance hemodialysis : manganism symptoms and T1 hyperintense changes in the basal ganglia" 28 : 1474-1479, 2007
• 83 Kullar SS, "A benchmark concentration analysis for manganese in drinking water and IQ deficits in children" 130 : 104889-, 2019